Systemic therapy for early-stage breast cancer: learning from the past to build the future.

Some years later, the EBCTCG confirmed these improvements in survival outcomes based on the pooled data of 30,000 women coming from a worldwide collaboration, where tamoxifen was associated with a highly significant reduction in the annual incidence of both disease recurrence and mortality (25% and 17%, respectively) 9 .

also in 132,142 other papers